Alkan, A., Güç, Z. G., Gürbüz, M., Özgün, G., Değirmencioğlu, S., Doğan, M., . . . Ürün, Y. (2021, September). Enzalutamide versus Abiraterone Acetate as first-line treatment of castration resistant metastatic prostate cancer in geriatric (≥75) patients. Journal of Men's Health.
Chicago Style (17th ed.) CitationAlkan, Ali, et al. "Enzalutamide Versus Abiraterone Acetate as First-line Treatment of Castration Resistant Metastatic Prostate Cancer in Geriatric (≥75) Patients." Journal of Men's Health Sep. 2021.
MLA (9th ed.) CitationAlkan, Ali, et al. "Enzalutamide Versus Abiraterone Acetate as First-line Treatment of Castration Resistant Metastatic Prostate Cancer in Geriatric (≥75) Patients." Journal of Men's Health, Sep. 2021.
Warning: These citations may not always be 100% accurate.